Loading...
NPI 1174576490 · Mattoon, IL · Medical Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Musaberk Goksel is a medical oncology physician provider located in Mattoon, Illinois. This profile covers 91 Medicare and 12 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Musaberk Goksel |
| Address | 1001 Health Center Dr |
| City | Mattoon |
| State | IL |
| ZIP | 61938 |
| Taxonomy | Medical Oncology Physician |
| NPI Enumerated | May 18, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $2.1M |
| Medicaid | $67.1K |
This provider is a Medical Oncology Physician with an NPI enumerated 2006-05-18 (~20 years ago) and shows a Medicare-dominant practice footprint: total Medicare revenue is $2.1M compared with total Medicaid revenue of $67.1K, indicating Medicare is the primary payor by scale. The long-tenured enrollment combined with the billing mix supports an established oncology practice focused on infusion-based therapies.
Medicare revenue is heavily concentrated in high-cost oncology drugs: the precomputed top 3 Medicare codes by revenue account for 71.9% of Medicare dollars, driven by J9271 ($705.2K, 34.6% of Medicare revenue), J9144 ($386.3K, 19.0%), and J9299 ($373.1K, 18.3%). All three codes are monoclonal antibody/immunotherapy injections (pembrolizumab, daratumumab, nivolumab), which indicates the provider’s revenue base is centered on expensive specialty drug administration.
While those three drug codes dominate Medicare dollars, this provider is not a national outlier in volume for those agents: J9271 ranks #592 of 1841 providers nationally (67th percentile, typical), J9144 ranks #190 of 615 (69th percentile, typical), and J9299 ranks #217 of 505 (57th percentile, typical). These rank positions suggest the provider is a modest-to-typical participant in high-cost immunotherapy administration rather than a national leader for any single agent.
Procedure and evaluation-and-management activity on Medicare further characterize the practice as an active infusion/E&M site: 99214 accounts for $80.6K (4.0% of Medicare revenue) and ranks #17053 of 479517 providers nationally (96th percentile, notably above typical national volume), while 96413 accounts for $56.6K (2.8%) and ranks #422 of 7514 (94th percentile, notably above typical national volume). High percentiles on both chemotherapy administration and higher-level E/M codes are consistent with a high-throughput oncology clinic that couples drug administration with significant practitioner visit time.
Medicaid activity is limited in scale but similarly concentrated: the precomputed top 3 Medicaid codes account for 78.4% of Medicaid revenue, with 96413 representing $35.6K (53.1% of Medicaid revenue) and ranking #42 of 149 providers in-state (72nd percentile, typical). The Medicaid profile shows chemotherapy administration is the dominant Medicaid revenue source, while office visits (99214 at $11.9K, 17.8%) form the next largest share, indicating the same service-line focus across payors but at much lower Medicaid volume.
The provider shows a mixed competitive stance: nationally for Medicare the drug revenues place the provider in a typical volume band for high-cost immunotherapies rather than as a dominant national center, while on state-level Medicaid metrics the provider’s chemotherapy administration (96413) sits in the upper-middle range of in-state peers (72nd percentile), implying reasonably strong local presence for infusion services. This pattern suggests local competitiveness for chemotherapy delivery paired with national-typical use of specific immunotherapies.
Beyond specialty drugs and E/M, several ancillary services show above-typical national activity consistent with an infusion setting: 36415 (phlebotomy) ranks in the 95th percentile nationally and both 80053 and 85025 (CMP and CBC panels) rank in the 94th percentile nationally. These high percentiles for routine lab and nursing procedures support the interpretation that the practice operates with substantial on-site infusion and monitoring throughput to support its drug administration revenue.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
91 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 16,400 | $40 | $705.2K |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 10,440 | $40 | $386.3K |
| J9299 | Injection, nivolumab, 1 mg | 16,220 | $20 | $373.1K |
| J0897 | Injection, denosumab, 1 mg | 8,760 | $20 | $157.7K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 850 | $100 | $80.6K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 600 | $100 | $56.6K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 440 | $90 | $37.7K |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | 350 | $100 | $33.4K |
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 30 | $1,070 | $30.1K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | 150 | $130 | $20.4K |
Showing 1–10 of 91
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 91 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
91 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 5 | 110 | 11,600 | $40 | $564.2K |
| J9144 | 2 | 50 | 7,740 | $40 | $341.8K |
| J9299 | 3 | 30 | 9,570 | $20 | $305.2K |
| J0897 | 6 | 410 | 2,520 | $20 | $90.8K |
| Q5122 | 2 | 30 | 410 | $90 | $44.1K |
| J0881 | 1 | 70 | 11,600 | $1 | $38.2K |
| J2506 | 2 | 70 | 320 | $80 | $32.9K |
| 78815 | 8 | 370 | 50 | $360 | $30.9K |
| J1439 | 3 | 80 | 25,500 | $1 | $30K |
| A9552 | 7 | 90 | 50 | $360 | $27.5K |
Showing 1–10 of 91
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
12 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 520 | $70 | $35.6K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 190 | $60 | $11.9K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 130 | $40 | $5K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 230 | $20 | $3.9K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 260 | $10 | $3.7K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 260 | $10 | $2.6K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 430 | $10 | $2.5K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 60 | $20 | $1.1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 210 | $1 | $210 |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 20 | $10 | $180 |
Showing 1–10 of 12
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
12 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 461 | 740 | 960 | $10 | $75.9K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 8,717 | 14,680 | 300 | $50 | $48.7K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 460 | 830 | 700 | $1 | $47.5K |
| 83735 | The lab analyst performs a test to measure the amount of magnesium in a patient specimen. | 293 | 310 | 1,690 | $1 | $40.3K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 42 | 150 | 170 | $50 | $39.9K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 9,140 | 14,190 | 280 | $20 | $38.9K |
| 96365 | The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease. | 56 | 80 | 150 | $40 | $29.3K |
| 96367 | The provider administers an additional intravenous infusion or infusions, after an initial infusion, of a different medication or substance for a period up to one hour to prevent, treat, or diagnose… | 23 | 40 | 280 | $30 | $17.4K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 30 | 80 | 120 | $20 | $17.1K |
| 96372 | A therapeutic, prophylactic, or diagnostic substance (a fluid, a drug, etc.) is injected via intramuscular or subcutaneous route into the patient's body. The procedure is performed by the physician… | 738 | 900 | 120 | $10 | $3.5K |
Showing 1–10 of 12
Other providers in the same ZIP code as Musaberk Goksel, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Coles County Mental Health Association, Inc. | IL | Mental Health Clinic/Center (Including Community Mental Health Center) | $0 | $17.2M |
| Hoopeston Community Memorial Hospital | IL | Rural Health Clinic/Center | $0 | $7.5M |
| Mitchell-jerdan Funeral Home Ltd | IL | Land Ambulance | $449.5K | $3M |
| Aziz Ahmed | IL | Diagnostic Radiology Physician | $611.2K | $1.1M |
| Joshua Garrett | IL | Diagnostic Radiology Physician | $275.4K | $976.9K |
| Matthew Jones | IL | Diagnostic Radiology Physician | $314.5K | $874.6K |
| Air Evac Ems, Inc. | IL | Air Ambulance | $879.9K | $189.7K |
| Nehemiah Tan | IL | Rheumatology Physician | $910.1K | $350 |
| Naresh Nekkanti | IL | Family Medicine Physician | $53.1K | $780.4K |
| Ragai Mitry | IL | Interventional Pain Medicine Physician | $157K | $571.1K |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.